文献速递瓣膜外科

非老年成人生物型主动脉瓣置换术后的长期结局与生活质量

Long-Term Outcome and Quality of Life After Biological Aortic Valve Replacement in Nonelderly Adults.
PubMed 文献 · Ann Thorac Surg · 2020-06-08

该回顾性队列纳入2005—2015年在本中心接受生物型主动脉瓣置换术的354例≤60岁连续患者,评估远期实际免于再干预率、MACCE及生活质量。平均随访78.7±38.1个月,5、10、12年实际免于AV再干预率分别为85.5%、67.8%、52.9%,实际免于MACCE分别为82.8%、63.2%、50.4%;心理生活质量优于已发表的年龄匹配对照人群,合并冠心病和基线肌酐是独立预测因素。

要点

  • ≤60岁患者生物型AVR后10–12年实际再干预与MACCE发生显著。
  • 心理生活质量优于已发表的年龄匹配对照人群,躯体生活质量相似。
  • 合并冠心病与基线肌酐是生存、再干预和MACCE的独立预测因素。

核心结论

  • ≤60岁患者生物型AVR在10–12年时实际AV再干预和MACCE发生显著。
  • 生物型AVR后心理生活质量优于已发表的年龄匹配对照人群。

研究设计与样本

  • 单中心回顾性队列,纳入2005—2015年接受生物型AVR的354例≤60岁连续患者。
  • 主要终点为实际免于AV再干预,次要终点为实际免于MACCE及心理与躯体生活质量。

主要发现

  • 平均年龄52.3±7.1岁,平均随访78.7±38.1个月。
  • 5、10、12年总生存率分别为87.6%、76.3%、63.5%。
  • 5、10、12年实际免于AV再干预率分别为85.5%、67.8%、52.9%。
  • 5、10、12年实际免于MACCE率分别为82.8%、63.2%、50.4%。
  • Cox回归显示合并冠心病(P<.001)和基线肌酐(P<.001)是生存、AV再干预和MACCE的独立预测因素。

临床怎么用

  • ≤60岁患者选择生物型瓣膜时需进行共享决策,充分告知10–12年再干预与MACCE风险。
  • 合并冠心病或基线肌酐升高者应加强术后随访与风险管控。

局限性

  • 单中心回顾性设计,结果外推需谨慎。
  • 摘要未报告对照组来源与匹配细节。
  • 最新一代生物瓣膜在年轻患者中的效果尚待评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Aortic valve replacement (AVR) is a standard of care in the treatment of aortic stenosis. The aim of the study was to evaluate the long-term outcome and quality of life (QoL) after biological AVR in patients younger than 60 years of age. METHODS: A total of 354 consecutive patients less than or equal to 60 years who underwent biological AVR at our institution (2005-2015) were included. The primary endpoint was actual freedom from AV reintervention, and secondary endpoints were actual freedom from major adverse cardiac and cerebrovascular events (MACCE) as well as mental and physical QoL. RESULTS: Mean age was 52.3 ± 7.1 years and mean follow-up duration was 78.7 ± 38.1 months. Overall survival at 5, 10, and 12 years was 87.6%, 76.3%, and 63.5%, and actual freedom from AV reintervention was 85.5%, 67.8%, and 52.9%, respectively. Actual freedom from MACCE was 82.8%, 63.2%, and 50.4%, respectively. Cox regression revealed concomitant coronary artery disease (P < .001) and creatinine at baseline (P < .001) as independent predictors of survival, AV reintervention, and MACCE. Physical QoL was similar (P = .427) and mental QoL (P = .005) was significantly better compared with the published age-matched control subjects. CONCLUSIONS: Biological AVR in patients less than or equal to 60 years of age is associated with a significant occurrence of actual AV reintervention and MACCE at 10 to 12 years. Mental QoL after biological AVR was superior compared with healthy control subjects. The effect of the most recently developed bioprosthesis, specifically for younger patients, needs to be evaluated. Therefore, a shared decision-making process in prosthetic AV selection is mandatory in AVR patients less than or equal to 60 years of age.

来源:Ann Thorac Surg,查看原文。版权归原作者所有。

引用

  1. Petersen J, Krogmann H, Reichenspurner H, et al. Long-Term Outcome and Quality of Life After Biological Aortic Valve Replacement in Nonelderly Adults. Ann Thorac Surg. 2020. PMID: 32526161. doi:10.1016/j.athoracsur.2020.04.097

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。